<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068702</url>
  </required_header>
  <id_info>
    <org_study_id>Optical Coherence Tomography</org_study_id>
    <nct_id>NCT03068702</nct_id>
  </id_info>
  <brief_title>New, Previously Unknown, Uses of Optical Coherence Tomography Angiography (OCTA)</brief_title>
  <acronym>OCTA</acronym>
  <official_title>New, Previously Unknown, Uses of Optical Coherence Tomography Angiography (OCTA): Sickle Cell Maculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. S.S. Michel Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. S.S. Michel Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell maculopathy was sparingly mentioned in the literature before despite the fact
      that sickle cell disease or sickle cell trait is common in people of many areas of the world.
      This study shows that OCTA is a very valuable, non invasive, office procedure that may well
      be used in diagnosing this disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      this is a clinical study of two African Canadian patients that were diagnosed with sickle
      cell trait. I used OCTA to show macular vascular occlusions that usually happen with this
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 21, 2016</start_date>
  <completion_date type="Actual">February 21, 2017</completion_date>
  <primary_completion_date type="Actual">January 12, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>vascular changes seen in the macular vasculature of people with sickle cell disease/ trait as compared to macular vasculature of normal macula.</measure>
    <time_frame>through study completion, an average of one year</time_frame>
    <description>in this angiography the delicate vasculature of the macula can be clearly visualized and documented.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2</enrollment>
  <condition>Sickle Cell Retinopathy</condition>
  <arm_group>
    <arm_group_label>African Canadians</arm_group_label>
    <description>African Canadians with sickle cell disease maculopathy diagnosed by OCTA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography Angiography</intervention_name>
    <arm_group_label>African Canadians</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        African Canadian adults
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: people with sickle cell trait or sickle cell disease -

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shawkat s Michel, MD, FRCS Ed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. S.S. Michel Clinic, 214 MHC, 156 street and 87 Ave, Edmonton, AB, Canada</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. S.S. Michel Clinic</investigator_affiliation>
    <investigator_full_name>Dr. Shawkat Michel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

